Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of adjuvanted CAD106 in mild Alzheimer's disease
2009-012394-35Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amilomotide in Alzheimer's disease (AD) (3 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability of CAD106 with Alum or MF59 and Amyloid beta- and Qbeta-specific antibody response. Started Dec 2009; status: completed.
02
Drugs
amilomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-012394-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012394-35.